Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Olusiji A. Akinrinmade"'
Autor:
Precious Hlongwane, Neelakshi Mungra, Suresh Madheswaran, Olusiji A. Akinrinmade, Shivan Chetty, Stefan Barth
Publikováno v:
Biomedicines, Vol 6, Iss 2, p 72 (2018)
Cancer immunotherapy aims to selectively target and kill tumor cells whilst limiting the damage to healthy tissues. Controlled delivery of plant, bacterial and human toxins or enzymes has been shown to promote the induction of apoptosis in cancerous
Externí odkaz:
https://doaj.org/article/cc54a3a76d5f43a58bf8257e0236ef27
Autor:
Sandra Jordaan, Olusiji A. Akinrinmade, Thomas Nachreiner, Christian Cremer, Krupa Naran, Shivan Chetty, Stefan Barth
Publikováno v:
Biomedicines, Vol 6, Iss 1, p 28 (2018)
Targeted cancer therapy includes, amongst others, antibody-based delivery of toxic payloads to selectively eliminate tumor cells. This payload can be either a synthetic small molecule drug composing an antibody-drug conjugate (ADC) or a cytotoxic pro
Externí odkaz:
https://doaj.org/article/66c4f9f9103a4660be7438b5d9de26a3
Autor:
Olusiji A. Akinrinmade, Shivan Chetty, Adebukola K. Daramola, Mukit-ul Islam, Theo Thepen, Stefan Barth
Publikováno v:
Biomedicines, Vol 5, Iss 3, p 56 (2017)
To date, no curative therapy is available for the treatment of most chronic inflammatory diseases such as atopic dermatitis, rheumatoid arthritis, or autoimmune disorders. Current treatments require a lifetime supply for patients to alleviate clinica
Externí odkaz:
https://doaj.org/article/2b062270a5b34f8fadcb49a87a9c3a1e
Autor:
Olusiji A. Akinrinmade, Sandra Jordaan, Dmitrij Hristodorov, Radoslav Mladenov, Neelakshi Mungra, Shivan Chetty, Stefan Barth
Publikováno v:
Biomedicines, Vol 5, Iss 3, p 36 (2017)
Some of the most promising small molecule toxins used to generate antibody drug conjugates (ADCs) include anti-mitotic agents (e.g., auristatin and its derivatives) which are designed to attack cancerous cells at their most vulnerable state during mi
Externí odkaz:
https://doaj.org/article/b58b69018c914f209e1a2ad9b38d89fb
Autor:
Allan M. Huysamen, Olaolu E. Fadeyi, Grace Mayuni, Dennis M. Dogbey, Neelakshi Mungra, Fleury A. N. Biteghe, Natasha Hardcastle, Dharanidharan Ramamurthy, Olusiji A. Akinrinmade, Krupa Naran, Susan Cooper, Dirk Lang, Wolfgang Richter, Roger Hunter, Stefan Barth
Publikováno v:
ACS Omega. 8:4026-4037
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::babf604561c325a4d7d0fba1b25f3431
https://doi.org/10.1021/acsomega.2c06844
https://doi.org/10.1021/acsomega.2c06844
Autor:
Mira Woitok, Elena Grieger, Olusiji A Akinrinmade, Susanne Bethke, Anh Tuan Pham, Christoph Stein, Rolf Fendel, Rainer Fischer, Stefan Barth, Judith Niesen
Publikováno v:
PLoS ONE, Vol 15, Iss 12, p e0243286 (2020)
In vitro and ex vivo development of novel therapeutic agents requires reliable and accurate analyses of the cell conditions they were preclinical tested for, such as apoptosis. The detection of apoptotic cells by annexin V (AV) coupled to fluorophore
Externí odkaz:
https://doaj.org/article/c05b4978132b4524b68c1177dd13fb04
Autor:
Tahir Bashir Dar, Fleury Augustin Nsole Biteghe, Ruchi Kakar-Bhanot, Eric Chekwebe Aniogo, Zaria Malindi, Olusiji Alex Akinrinmade, Nyangone Ekome Toung Chalomie, Arnaud John Kombe Kombe, Sophie Aboughe Angone, Jean Marc Ngome Ndong, Jean Delacroix Ndong
Publikováno v:
Clinical and Translational Oncology. 24:2255-2271
Radiotherapy (RT), unlike chemotherapy, is one of the most routinely used and effective genotoxic and immune response inducing cancer therapies with an advantage of reduced side effects. However, cancer can relapse after RT owing to multiple factors,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89074c9ba43adbb0e2b10fd31592bd56
https://doi.org/10.1007/s12094-022-02888-7
https://doi.org/10.1007/s12094-022-02888-7
Autor:
Rolf Fendel, Olusiji A. Akinrinmade, Elena Grieger, Mira Woitok, Stefan Barth, Susanne Bethke, Anh Tuan Pham, Judith Niesen, Christoph Stein, Rainer Fischer
Publikováno v:
PLoS ONE, Vol 15, Iss 12, p e0243286 (2020)
PLOS ONE 15(12), e0243286 (2020). doi:10.1371/journal.pone.0243286
PLoS ONE
PLOS ONE 15(12), e0243286 (2020). doi:10.1371/journal.pone.0243286
PLoS ONE
PLOS ONE 15(12), e0243286 (2020). doi:10.1371/journal.pone.0243286
Published by PLOS, San Francisco, California, US
Published by PLOS, San Francisco, California, US
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51345232a46621c440d1f744167d0e1a
https://doaj.org/article/c05b4978132b4524b68c1177dd13fb04
https://doaj.org/article/c05b4978132b4524b68c1177dd13fb04
Autor:
Neelakshi Mungra, Olusiji A. Akinrinmade, Suresh Madheswaran, Stefan Barth, Precious Hlongwane, Shivan Chetty
Publikováno v:
Biomedicines, Vol 6, Iss 2, p 72 (2018)
Biomedicines
Biomedicines
Cancer immunotherapy aims to selectively target and kill tumor cells whilst limiting the damage to healthy tissues. Controlled delivery of plant, bacterial and human toxins or enzymes has been shown to promote the induction of apoptosis in cancerous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e879c7dd485185e5f0204f7586b4e63a
http://www.mdpi.com/2227-9059/6/2/72
http://www.mdpi.com/2227-9059/6/2/72
Autor:
Shivan Chetty, Neelakshi Mungra, Sandra Jordaan, Olusiji A. Akinrinmade, Dmitrij Hristodorov, Radoslav Mladenov, Stefan Barth
Publikováno v:
Biomedicines, Vol 5, Iss 3, p 36 (2017)
Biomedicines
Biomedicines
Some of the most promising small molecule toxins used to generate antibody drug conjugates (ADCs) include anti-mitotic agents (e.g auristatin and its derivatives) which are designed to attack cancerous cells at their most vulnerable state during mito
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::586f97c028801982f900a97b4da2b01e
https://publica.fraunhofer.de/handle/publica/253674
https://publica.fraunhofer.de/handle/publica/253674
